Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Now, researchers are on the threshold of great changes that have the potential to transform non-curable diseases into those that can be cured.
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
Shares of Moderna are down nearly 10% this morning despite the company posting positive interim results from an experimental seasonal flu vaccine.
Innocoll Biotherapeutics, Genapsys, and Adicet Bio announced today their relocation and expansion plans.
Roche announced promising results from the Phase II CITYSCAPE study of tiragolumab plus Tecentriq compared to Tecentriq alone as a treatment for PD-L1-positive metastatic NSCLC.
A new study conducted on a 35-year-old blood and stool sample provides new insights into HIV research and the role the gut microbiome may have played in infection among infected individuals.
A team of Yale researchers has found a key to unlocking the deadly mystery of brain aneurysms in adults.
The 2021 San Antonio Breast Cancer Symposium is meeting December 7–10 at the Henry B. Gonzalez Convention Center in San Antonio, Texas, and virtually.
Eli Lilly forged a multi-year collaborative partnership with China-based Regor Therapeutics Group to discover and develop new therapies that will be aimed at metabolic disorders.
The best way to battle the dominant Delta strain is booster vaccines. So far, initial data suggests boosters are likely to help battle Omicron as well. For that and more COVID-19 news, read on.
A U.S. Congress subcommittee unanimously approved the ACT for ALS bill in a decision that could soon pour massive funding into the search for treatment for this debilitating and deadly disease.
CSL Behring and uniQure announced that their etranacogene dezaparvovec hit the pre-specified primary endpoint in their Phase III clinical trial in severe to moderately severe hemophilia B.